Tuesday, 20 Nov 2018

You are here

Tumor Necrosis Factor Inhibitors Do Not Increase the Risk of Cancer Recurrence

There is a large body of data that shows tumor necrosis factor inhibitors (TNFi) use in rheumatoid arthritis (RA) confers the same risk as that seen in RA - meaning there is no increase over and above that incurred by inflammation and RA itself.  There are fewer studies about whether it is safe to use a TNFi in someone with a pre-existing history of cancer.

Raaschou and colleagues have performed a cohort comparison of RA patients, in a prospective Swedish database, who were diagnosed with cancer between 2001 and 2015 and were either treated with a TNFi or were never given a biologic agent. The primary outcome was the first recurrence of cancer.

Among the 467 RA patients who started TNFi treatment (a mean of 7.9 years after a cancer diagnosis), the recurrence of cancer was seen in 42 TNFi treated patients (9.0%).  

Among 2164 matched patients with the same cancer history but were biologic naive, 155 had a cancer recurrence (7.2%).

Thus, while there were a few more numerically, these results were not significantly different (HR, 1.06 [95% CI, 0.73 to 1.54).

The authors speculate that channeling bias was possible if patients with a better index cancer prognosis were more likely to receive TNFi, but there is no data to corroborate this.

The authors conclude that while TNFi treatment is not associated with increased risk for cancer recurrence in RA, they speculate that meaningful risk increases could not be ruled out completely.

These data are similar to that these authors have previously published showing no increased risk of dying from cancer if TNFi was given to someone with a history of cancer. What is encouraging about this data is that this is one of the largest cohorts examined for cancer recurrence and no risk was proven.  Moreover, these patients with a long past history of cancer went on to safely receive a TNFi without added cancer risk.

Rheumatologists should treat the arthritis as aggressively as is necessary and leave cancer management, monitoring and screening to the oncologists. 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Growing Tick Population Comes with Health Concerns

CNN has published a recent government report from the Tick-Borne Disease Working Group that suggests the US tick population is growing and may bring with it an increase in tick-related illnesses. 

While Lyme disease is the most popular of tick-borne illnesses, there are another 20 known conditions related to tick bites.

Chikungunya Virus Vaccine Developed

Lancet reports on a new vaccine for Chikungunya fever (MV-CHIK) demonstraing excellent safety, tolerability and good immunogenicity, independent of pre-existing immunity against the vector. MV-CHIK is a promising vaccine for the prevention of chikungunya fever.

Subclinical Heart Inflammation Seen in RA

Subclinical myocardial inflammation is common among patients with rheumatoid arthritis (RA) and is associated with articular disease activity, researchers reported.

A New Era? JAK inhibitors in the Management of RA

ACR 2018 has come and gone. It was a conference filled with a number of highlights. One thing from this conference which really stood out was the continued plethora of data on JAK inhibitors. First in RA, and now in psoriatic arthritis and psoriasis.

Spotlight on Interstitial Lung Disease at ACR 2018

Here are a few important advances in our understanding of interstitial lung disease (ILD) from the ACR 2018 meeting last week.